5-(N,N-dimethyl)-Amiloride (hydrochloride): Precision NHE1 Inhibition for Cardiovascular Research

Executive Summary:
5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a crystalline inhibitor of Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3, with sub-micromolar Ki values under standard buffer conditions (APExBIO). It enables precise modulation of intracellular pH and sodium ion homeostasis in mammalian cell models. DMA demonstrates protective effects in cardiac ischemia-reperfusion injury by normalizing sodium levels and contractility (Chen et al., 2021). Its selectivity profile minimizes off-target effects on related exchangers (NHE4, NHE5, NHE7). The compound is validated for reproducible, high-impact workflows in cardiovascular and endothelial dysfunction research (see comparison).

Biological Rationale

The Na+/H+ exchanger (NHE) family regulates intracellular pH by extruding protons (H+) and importing sodium ions (Na+) across the plasma membrane (Chen et al., 2021). NHE1 is ubiquitously expressed in mammalian cells and is critical for cell volume control, signal transduction, and protection against acid loads. Dysregulation of NHE1 activity contributes to pathologies such as cardiac ischemia-reperfusion injury, sepsis-induced endothelial dysfunction, and hypertension (Advancing Translational Research). Inhibiting NHE1 has been shown to attenuate cytosolic Na+ overload, maintain pH homeostasis, and protect against contractile dysfunction. 5-(N,N-dimethyl)-Amiloride (hydrochloride), supplied by APExBIO, offers high selectivity for NHE1, NHE2, and NHE3, enabling targeted investigation of Na+/H+ exchanger signaling in cardiovascular and endothelial models.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA acts as a competitive inhibitor of Na+/H+ exchangers, binding to the extracellular domain of NHE1, NHE2, and NHE3 with Ki values of 0.02 µM, 0.25 µM, and 14 µM respectively (buffered to pH 7.4, 37°C). It prevents the extrusion of protons and entry of sodium ions, resulting in intracellular acidification and reduced sodium influx (APExBIO). This modulation of ionic homeostasis disrupts secondary processes such as ATPase activity and alanine uptake in hepatocytes. DMA’s negligible effect on NHE4, NHE5, and NHE7 ensures minimal interference with non-targeted isoforms (see advanced pathway mapping).

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 µM under physiological conditions, outperforming non-dimethylated amiloride derivatives (APExBIO).
• In rat cardiac tissue models, DMA prevents sodium overload and preserves contractile function after ischemia-reperfusion (Chen et al., 2021).
• DMA selectively spares NHE4, NHE5, and NHE7, as confirmed by transporter-specific flux assays (internal review).
• DMA inhibits ouabain-sensitive ATP hydrolysis and sodium-potassium ATPase activity in rat liver plasma membranes, indicating broader impacts on sodium transport (APExBIO).
• Alanine uptake is significantly reduced in hepatocytes exposed to DMA, reflecting metabolic coupling to NHE inhibition (internal protocol).
• DMA is soluble up to 30 mg/ml in DMSO and DMF at ambient temperature; solutions are stable for short-term use only (APExBIO).

Applications, Limits & Misconceptions

DMA is validated for the following research applications:

• Dissection of Na+/H+ exchanger signaling pathways in cardiovascular and endothelial injury models (detailed guide).
• Protection against contractile dysfunction and sodium overload in ischemia-reperfusion injury research, extending findings from prior NHE1 inhibitors (workflow optimization article).
• Assessment of endothelial barrier function and pH regulation in response to inflammatory stimuli, clarifying the role of NHE1 in sepsis models (Chen et al., 2021).

Common Pitfalls or Misconceptions

• DMA is not a diagnostic or therapeutic agent. It is strictly for in vitro or ex vivo research use; clinical applications are unproven.
• Long-term solution storage reduces activity. Freshly prepared DMA solutions are required for reproducible inhibition (APExBIO).
• DMA does not effectively inhibit NHE4, NHE5, or NHE7. Studies targeting these isoforms require alternate inhibitors.
• Effects on ATPases and alanine uptake are secondary. Primary action is via NHE1–3 inhibition; metabolic effects may be cell-type dependent.
• Interpretation of results requires strict ionic and pH control. Buffer and temperature conditions critically impact inhibitor potency and selectivity.

Workflow Integration & Parameters

DMA (C3505) from APExBIO is supplied as a crystalline solid, soluble up to 30 mg/ml in DMSO or dimethyl formamide. Standard experimental concentrations range from 0.01–10 µM for NHE1 inhibition in mammalian cell culture (37°C, pH 7.2–7.4 buffers). Solutions should be freshly prepared and stored at -20°C; extended storage reduces potency. For cardiac ischemia-reperfusion models, pre-incubation for 15–30 min is typical. Ion flux and pH measurements should be calibrated for each cell type. For troubleshooting and advanced applications, see the protocol-focused comparison: Optimizing NHE1 Inhibition Workflows, which this article extends by providing new evidence for sodium-potassium ATPase modulation.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) is a benchmark tool for selective Na+/H+ exchanger inhibition in cardiovascular, metabolic, and endothelial research. Its high specificity for NHE1–3, validated effects on sodium and pH homeostasis, and rigorous workflow compatibility empower translational studies of contractile dysfunction and vascular injury. For detailed product information and ordering, visit the APExBIO C3505 product page. This article clarifies and extends prior guides by integrating recent evidence for ATPase modulation and metabolic effects, supporting robust experimental design in sepsis and cardiac injury models.